---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-100891"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:42:17.517995+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge

## Summary
- Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.
- Diagnostics revenue $101.1M (-22% YoY) on lower clinical test volume from BioReference asset sale; operating loss improved to $18.2M from $26.6M.
- Pharmaceuticals revenue $40.7M (flat); operating loss $28.7M vs $24.8M, driven by higher R&D for pipeline programs.
- Board authorized additional $100M share repurchase, total capacity $200M; $58.5M repurchased through June 30.
- FDA approved 4Kscore Test without DRE; Merck Phase 1 EBV vaccine and multiple pipeline programs advancing.

## SEC filing metadata
- accession: 0000950170-25-100891
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000095017025100891/0000950170-25-100891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000095017025100891/opk-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-100891
- JSON: https://secwatch.observer/filing/0000950170-25-100891.json
- Plain text: https://secwatch.observer/filing/0000950170-25-100891.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.